Previous Next Low-value Care Five Important Questions About Pfizer’s COVID-19 Vaccine Abstract: The drugmaker says its mRNA vaccine worked in 90% of patients in its trial, but some observers question how long immunity will last and who will benefit. Publication: Kaiser Health News Date Published: November 11, 2020 Author(s): Arthur Allen View This Resource